Advances in immune checkpoint inhibitors induced-cardiotoxicity
Frontiers in Immunology · 23.02.2023 · 14
DOI: 10.3389/fimmu.2023.1130438 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, online erschienen am 23.02.2023. Verfasst von Xiang Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of the Second Medical Oncology, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) are approved as the first-line drug for treating many cancers and has shown significant survival benefits; however, it also causes immune-related adverse events (irAEs) while activating the immune system, involving multiple organs. Among them, cardiovascular immune-related adverse events (CV-irAE) are rare, but common causes of death in ICIs treated cancer patients, which manifest as myocardial, pericardial, vascular and other cardiovascular toxicities. Therefore, it is important that irAEs, especially CV-irAE should be carefully recognized and monitored during the whole ICIs treatment because early detection and treatment of CV-irAE can significantly reduce the mortality of such patients. Consequently, it is urgent to fully understand the mechanism and management strategies of CV-irAE. The effects of ICIs are multifaceted and the exact mechanism of CV-irAE is still elusive. Generally, T cells identify tumor cell antigens as well as antigen in cardiomyocytes that are the same as or homologous to those on tumor cells, thus causing myocardial damage. In addition, ICIs promote formation of cardiac troponin I (cTnI) that induces cardiac dysfunction and myocardial dilatation; moreover, ICIs also increase the production of cytokines, which promote infiltration of inflammation-linked molecules into off-target tissues. Currently, the management and treatment of cardiovascular toxicity are largely dependent on glucocorticoids, more strategies for prevention and treatment of CV-irAE, such as predictive markers are being explored. This review discusses risk factors, potential pathophysiological mechanisms, clinical manifestations, and management and treatment of CV-irAE, guiding the development of more effective prevention, treatment and management strategies in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of the Second Medical Oncology, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
- Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, TX, United States.
Zitieren
APA
Li, X., Peng, W., Wu, J., Yeung, S. J., & Yang, R. (2023). Advances in immune checkpoint inhibitors induced-cardiotoxicity. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1130438
Vancouver
Li X, Peng W, Wu J, Yeung SJ, Yang R. Advances in immune checkpoint inhibitors induced-cardiotoxicity. Frontiers in Immunology. 2023;14. doi:10.3389/fimmu.2023.1130438
BibTeX
@article{Li2023,
author = {Li, Xiang and Peng, Wenying and Wu, Jiao and Yeung, Sai-Ching Jim and Yang, Runxiang},
title = {Advances in immune checkpoint inhibitors induced-cardiotoxicity},
journal = {Frontiers in Immunology},
year = {2023},
volume = {14},
doi = {10.3389/fimmu.2023.1130438}
}
EUVIMED